Mutation will not reduce the effectiveness of inactive Kovid-19 vaccines
Ankara University Faculty of Medicine Faculty Member Prof. Dr. Taner Demirer stated that the inactive (dead virus) vaccine is the type of vaccine that will not be affected by the mutated new type of coronavirus or will be least affected.
Iron, AA said in a statement to reporters in the world and in Turkey Kovid-19 outbreak of continued that attract attention of individuals complacency doors without a mask, pointed out the importance of adherence to the distance and hygiene rules.
Stating that coronaviruses are one of the frequently mutated viruses, Demirer said, "We saw the mutated virus first in England, then in Brazil and South Africa. The authorities in South Africa stated that the mutated virus seen in this country may be more resistant to existing mRNA vaccines. were. " said.
Iron is, a mutated virus in Turkey as well as in other countries, recalling that at any moment could be seen in some provinces drew attention to the emergence of different mutations.
Expressing that the small-scale mutations experienced so far have not reduced the effectiveness of existing Kovid-19 vaccines, Demirer stated that it may take 4-6 weeks to produce a new mRNA vaccine in case of large-scale mutations, and that new vaccine compositions have already been prepared in Europe.
"We do not expect dead vaccines to be affected by the mutation"
Turkey also started to be inactivated polio vaccine that is not affected by the mutation of expressing Demir said:
"Dead vaccines are not affected by mutation. Because mRNA vaccines produce antibodies only against the thorn protein of the virus. But dead vaccines create antibodies against all 4 parts of the virus, namely the thorn protein, the envelope, the nucleus and the outer membrane. These vaccines will not lose their effectiveness.
I think Europe and North America will turn to dead vaccines if mutations become widespread in the upcoming period. Because until this time, dead vaccines and safe vaccines were given to 2 million people in our country. These are vaccines that will not or will be least affected by the mutation. Because there is antibody formation against all components of the virus. For this reason, dead vaccination studies have started in Northern Europe. "
"The goal is to vaccinate 25 million people by the end of April"
Demirer stated that in order to prevent mutations, as many people as possible should be vaccinated in a short time:
"For example, the goal in our country is to vaccinate 25 million people, one third of our society by the end of April. Considering the existence of mutations, we will be advantageous if we reach this goal.
It should not be forgotten that we should be careful about mutations across the country. The Ministry of Health takes the necessary measures at airports and borders. We need to comply with mask, distance and hygiene rules. People from crowded and closed places, especially in winter,